title: Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.
abstract: OBJECTIVE
  Since the results of the ATAC study, women who have undergone surgery for breast cancer and who require adjuvant hormone therapy are often treated with aromatase inhibitors. With these treatments, joint pain is frequent (30% to 40%) and quite often disabling (5% to 10%). Our objective was to investigate the origin of the pain induced by the anti-aromatases.
  
  
  METHODS
  Twenty-four women of mean age 59 years with joint pain of > 5/10 on a visual analog scale underwent a rheumatological consultation and systematic laboratory tests.
  
  
  RESULTS
  In 5 patients, pain was considered to have a well defined cause: osteoarthritis, shoulder tendinitis, or paraneoplastic aponeurositis. The other 19 patients had inflammatory pain of the fingers, wrists, shoulders, forefeet, ankles, or knees, with slight synovial thickening of the PIP and MCP joints. Two had an inflammatory syndrome on laboratory tests. Nine of these patients had antinuclear antibodies (ANA > 1/160 on HEp-2 cells) and 4 had rheumatoid factors (> 20 U). Ten patients had sicca syndrome of the eyes or mouth, 7 had probable Sjögren's syndrome according to the San Diego criteria, and one had definite Sjögren's syndrome. One had rheumatoid arthritis, one had Hashimoto thyroiditis, and 2 had positive hepatitis C serology.
  
  
  CONCLUSIONS
  Is the almost total estrogen depletion induced by aromatase inhibitors conducive to the development of sicca syndromes with ANA? Our results should be considered in relation to the Sjögren-like syndromes occurring in aromatase knock-out mice as recently reported.
authors.affiliation: Service de Rhumatologie, CHU Rangueil, 1 Avenue Jean Poulhès, Toulouse, France. laroche.m@chu-toulouse.fr
authors.forename: Michel
authors.initials: M
authors.lastname: Laroche
authors.forename: Séverine
authors.initials: S
authors.lastname: Borg
authors.forename: Slim
authors.initials: S
authors.lastname: Lassoued
authors.forename: Brigitte
authors.initials: B
authors.lastname: De Lafontan
authors.forename: Henri
authors.initials: H
authors.lastname: Roché
mesh_terms: D000368:Aged; D000077384:Anastrozole; D000974:Antibodies, Antinuclear / Q000097:blood; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D047072:Aromatase Inhibitors / Q000009:adverse effects*; D018771:Arthralgia / Q000209:etiology*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D020847:Estrogen Receptor Modulators / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D009570:Nitriles / Q000009:adverse effects; D012859:Sjogren's Syndrome / Q000209:etiology* / Q000276:immunology; D013629:Tamoxifen / Q000009:adverse effects; D014230:Triazoles / Q000009:adverse effects
chemical_list: D000974:Antibodies, Antinuclear; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D020847:Estrogen Receptor Modulators; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole